Anticancer Drugs

Logo Daily Mail
HealthBy Luke Andrews2023-03-24 15:54:20
An experimental pill for leukemia has shown promise in early clinical trials sending a third of patients with aggressive disease into complete remission. The...

Logo PR Newswire
HealthPress Release2023-03-24 12:00:00
WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel...

Logo PR Newswire
HealthPress Release2023-03-24 14:01:00
SILVER SPRING, Md., March 24, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued draft guidance, Clinical Trial Considerations to...

Logo PR Newswire
HealthPress Release2023-03-25 02:00:00
DUBLIN, March 24, 2023 /PRNewswire/ -- The "Pancreatic Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering....

Logo PR Newswire
FN Media Group Presents USA News Group News Commentary VANCOUVER, British Columbia, March 24, 2023 /PRNewswire/ -- USA News Group - Treatments for various...

Logo Nasdaq
Business / FinanceBy Rtt News2023-03-24 10:48:35
(RTTNews) - GSK PLC (GSK.L, GSK) issued a statement as response to Sargon ruling by the California state court in respect of the Goetz case. The company...

Logo GlobeNewswire
SciencePress Release2023-03-23 12:00:00
Media Release 2 nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help...

Logo Nasdaq
Business / FinanceBy Rtt News2023-03-24 10:52:29
(RTTNews) - Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib...

Logo PR Newswire
HealthPress Release2023-03-24 13:00:00
First in human study will evaluate safety, tolerability, and pharmacokinetic parameters of NRL-1049, a Rho kinase (ROCK) inhibitor SAN DIEGO, Calif., March...

Logo EIN Presswire
HealthPress Release2023-03-24 13:02:59
Ovarian Cancer Drugs Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032 The Business Research Company's Ovarian Cancer Drugs...

Logo PR Newswire
HealthPress Release2023-03-23 10:11:00
CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- ONO PHARMA USA, INC., announced that its candidate, tirabrutinib (ONO-4059), a Bruton's tyrosine kinase...

Logo Daily Mail
Business / FinanceBy Calum Muirhead2023-03-24 21:51:09
GlaxoSmithKline suffered a blow after a US judge ruled against it in a lawsuit relating to its heartburn drug Zantac. The FTSE 100 pharmaceuticals group and...

Logo GlobeNewswire
SciencePress Release2023-03-24 07:30:00
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included 20M upfront...

Logo PR Newswire
HealthPress Release2023-03-23 10:30:00
CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely...

Logo EIN Presswire
SciencePress Release2023-03-23 23:59:32
LANDMARK INTERNATIONAL COLLABORATION CREATES A FOUNDATION FOR DRUG DEVELOPMENT IN YOUNG ADULT CANCER CALLED CCS, OPENING THE DOOR TO NEW POTENTIAL THERAPY...

Logo GlobeNewswire
SciencePress Release2023-03-23 21:01:00
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of...

Logo PR Newswire
HealthPress Release2023-03-24 12:54:00
LOS ANGELES, March 24, 2023 /PRNewswire/ -- Waismann Method®, a reputable addiction treatment center, is calling for urgent nationwide action to address the...

Logo PR Newswire
HealthPress Release2023-03-24 18:00:00
NEW YORK, March 24, 2023 /PRNewswire/ -- The non-hodgkin lymphoma therapeutics market size is forecast to grow by USD 5,427.51 million between 2022 and 2027,...

Logo GlobeNewswire
SciencePress Release2023-03-23 11:30:00
BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings...

Logo GlobeNewswire
SciencePress Release2023-03-23 20:05:00
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...